Navigation Links
Surveyed U.S. Pulmonologists Expect to Treat Nearly 50 Percent of Their Severe, Refractory Asthma Patients With a Biologic or Biosimilar Version of Xolair By the End of 2018
Date:4/9/2013

BURLINGTON, Mass., April 9, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. pulmonologists estimate that only 19 percent of their severe, refractory asthma patients are treated with Genentech/Novartis's Xolair, the only approved drug that serves this population. However, by the end of 2018, when three novel biologics and biosimilar versions of Xolair are expected to be available, surveyed pulmonologists estimate that nearly 50 percent of their severe, refractory patients will be treated. This response demonstrates the great unmet need for this population that will be at least partially filled by the emerging biologics.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The new U.S. Physician & Payer Forum report entitled How Will U.S. Physician and Payer Attitudes and Decisions Shape the Asthma Market for Patients with Severe, Refractory Disease? also finds that most surveyed pulmonologists are receptive to prescribing biosimilar versions of Xolair in their first year of availability and intend to prescribe Boehringer Ingelheim/Pfizer's Spiriva upon its approval for asthma. As a result, these prescribing habits could delay prescribing of branded biologics to a later line of therapy.

The report also finds that surveyed managed care organization (MCO) pharmacy and medical directors' expected formulary tier positions of emerging biologics depend on price more so than potential Phase III clinical trial results, suggesting that price point is important for ensuring favorable formulary coverage despite the unmet need for additional treatment options for severe, refractory asthma.

"Surveyed payers indicated that the most common restriction placed on the emerging biologics will be prior authorization, which is similar to what is currently in place for Xolair," said Decision Resources Analyst Colleen Albacker , Ph.D. "Forty-one percent of patients eligible for Xolair never receive the drug, with pulmonologists citing cost- and reimbursement-related issues as the major reasons, and the emerging biologics may face the same fate due to payer cost controls."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
2. Surveyed U.S. and European Neurologists Agree that a Therapys Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
3. Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
4. Surveyed U.S. Physicians Indicate That Xarelto and Apixaban Will Benefit From the Lack of Use of a Fast-Acting Injectable Anticoagulant in the Treatment and Secondary Prophylaxis of Deep Vein Thrombosis/Pulmonary Embolism
5. Surveyed U.S. Neurologists Would Prescribe Biogen Idecs Tecfidera to 20 Percent of Their Patients with Relapsing-Remitting Multiple Sclerosis (RR-MS)
6. Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth
7. ChromaDex® Experiencing Higher Than Expected Demand For Its Recently Launched BluScience™ Line of Dietary Supplements
8. China Botanic Sponsors Wild Plant Protection Association of China Meeting; Expects to Lead the Siberian Ginseng Conservation Association
9. Johnson & Johnson Expects to Incur Special Charge in Second Quarter for Previously Disclosed Legal Matters
10. Asthma and COPD Drug Market Expected to Reach USD 26,965.5 Million Globally in 2017: Transparency Market Research
11. Medical Alarm Lands European Order with Additional Orders Expected
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016  Walgreens has committed to ... states and Washington, D.C. as part ... that was commended by shareholder advocacy organization As You Sow. ... You Sow. "Many people hold on to unneeded drugs because ... have tragic consequences." --> Conrad MacKerron , ...
(Date:2/11/2016)... , Feb. 11, 2016  NOIT™ Research LLC, a ... "Gift of Change" campaign to assist needy families in ... such unit sold between February 10, 2016 and March ... a needy family. The NOIT is an auditory stimulus ... individuals develop language skills. Beth Shier ...
(Date:2/11/2016)... and PORTLAND, Ore. , ... 340B optimization company, is pleased to announce the acquisition ... sole community and rural access hospitals. Along with providing ... of 340B consulting services to assist clients in navigating ... R. Love , CEO of Wellpartner. --> ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... ... Every winter, someone is killed, injured or loses a home in an accident ... of the Allegheny Health Network, has partnered with Etna Volunteer Fire Department, and Monroeville ... , “Space Heaters Need Space” aims to bring awareness to the risks ...
(Date:2/12/2016)... Arlington, TX (PRWEB) , ... February 12, 2016 , ... ... Worth, and other communities across eastern Texas, is launching a cooperative charity drive with ... and families. , Serving more than 50,000 individuals and families in need, the Tarrant ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... the Pittsburgh metro area, celebrates the beginning of the latest charity campaign in ... social skills through art. Donations to this worthy cause are currently being accepted ...
(Date:2/12/2016)... FL (PRWEB) , ... February 12, 2016 , ... For ... Dental hygienist Suzan Sweeney, RDH, and dental assistant Terrell Moore shortly before 7 a.m. ... joined dozens of dental professionals, donating their time and skills to help hundreds of ...
(Date:2/12/2016)... OR (PRWEB) , ... February 12, 2016 , ... ... an article about foods choices that promote eye health. These articles generally list ... health. Water and health advocate Sharon Kleyne endorses every one of these lists ...
Breaking Medicine News(10 mins):